Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer With Durable Disease Control: A Randomized Low-intervention Phase II Trial of the AIO Working Groups Breast Cancer and Quality of Life
This is a low-intervention, randomized, non-comparative, open-label, multicenter, prospective, phase II trial investigating discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control.
100 项与 Institut fr Klinische Krebsforschung IKF GmbH 相关的临床结果
0 项与 Institut fr Klinische Krebsforschung IKF GmbH 相关的专利(医药)
100 项与 Institut fr Klinische Krebsforschung IKF GmbH 相关的药物交易
100 项与 Institut fr Klinische Krebsforschung IKF GmbH 相关的转化医学